FDA clears Johnson & Johnson’s oral psoriasis drug Icotyde

Johnson & Johnson said the US Food and Drug Administration approved Icotyde, the brand name for icotrokinra, on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents age 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. The company is positioning Icotyde as the first approved targeted oral peptide that selectively blocks the IL-23 receptor, offering a once-daily pill instead of an injectable biologic. The approval follows Johnson & Johnson’s Phase 3 ICONIC program, including ICONIC-LEAD and ICONIC-ADVANCE studies, and comes as the company continues to expand its dermatology portfolio around IL-23 pathway therapies. (jnj.com)

Why it matters: For veterinary professionals, this is mainly a market and regulatory signal rather than a clinical one. It shows how quickly oral, targeted immunology drugs are moving into disease areas long dominated by injectables, and how companies are using convenience, adherence, and earlier systemic use as part of their value story. That trend can influence pet parent expectations around chronic inflammatory disease treatment, even outside human dermatology, and may shape broader industry thinking about oral peptide development, specialty pharmacy access, and long-term safety monitoring for immune-modulating therapies. The competitive pressure is also building: Takeda presented Phase 3 LATITUDE data at AAD 2026 showing strong 16-week skin clearance results for oral TYK2 inhibitor zasocitinib versus both placebo and apremilast, with responses improving through Week 24 and durability above 90% at Week 60 in one study, reinforcing that the oral immunodermatology race is accelerating. (jnj.com; PharmaShots/Takeda AAD 2026 summary)

What to watch: Watch for payer coverage decisions, uptake versus established psoriasis brands, and whether Johnson & Johnson can extend icotrokinra into additional inflammatory indications such as ulcerative colitis. Also watch Takeda’s planned regulatory filings for zasocitinib starting in its fiscal 2026, because a second strong oral entrant could sharpen competition on efficacy, convenience, and real-world value. (innovativemedicine.jnj.com; PharmaShots/Takeda AAD 2026 summary)